Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination

Cancer Immunology, Immunotherapy

Volumn 51, Issue 4, 2002, Pages 179-189

  Graf, Martin R ^a   Prins, Robert M ^b   Hawkins, William T ^a   Merchant, Randall E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cytotoxic T lymphocyte; Glioma immunity; Glioma vaccine; Radiotherapy

Indexed keywords

CYTOKINE; HEMOSIDERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BREAST ADENOCARCINOMA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER TRANSPLANTATION; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; EDEMA; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; INFLAMMATION; INTRACRANIAL TUMOR; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RAT; T LYMPHOCYTE; TARGET CELL; TH1 CELL; TUMOR GROWTH; TUMOR LOCALIZATION; VACCINATION;

ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; FEMALE; GLIOMA; LYMPHOCYTES, TUMOR-INFILTRATING; RATS; RATS, INBRED F344; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0036252635     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0269-3     Document Type: Article

References (50)

1. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes
2. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases
3. Rat brain tumor models in experimental neuro-oncology: The 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas
4. Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture
5. Inflammatory leukocytes associated with increased immunosuppression by glioblastoma
6. Failure of cancer vaccines: The significant limitations of this approach to immunotherapy
7. Cell therapy: Achievements and perspectives
8. + cells localize selectively in rat 9L gliosarcomas but have reduced cytolytic function
9. Malignant glioma - A nemesis which requires clinical and basic investigation in radiation oncology
10. Immune defects observed in patients with primary malignant brain tumors
11. Self recognition by T cells. I. Bystander killing of target cells bearing syngeneic MHC antigens
12. Antitumor vaccination using peptide-based vaccines
13. Characterization of lymphoid cells isolated from human gliomas
14. Dendritic cells in cancer immunotherapy
15. + T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity
16. Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor
17. Interleukin-6 transduction of a rat T9 glioma clone results in attenuated tumorigenicity and induces glioma immunity in Fischer F344 rats
18. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity
19. Increasing annual incidence of primary malignant brain tumors in the elderly
20. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells
21. Cancer vaccines: An update
22. Lysis of innocent bystanders by antigen-specific cytotoxic lymphocytes
23. The future of therapy for glioblastoma
24. Cellular therapy of brain tumors - Clinical trials
25. Tumor angiogenesis - A new therapeutic target in gliomas
26. Cytokine-secreting tumor cell vaccines
27. Interleukin-2, the cerebrovasculature, and the treatment of malignant glioma
28. Immunotherapy for malignant glioma using human recombinant interleukin- 2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations
29. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine-activated killer cells and recombinant interleukin-2
30. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial
31. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor
32. Genetically modified tumour vaccines - Where we are today
33. Dendritic cell based tumor vaccines
34. Design and evaluation of antigen-specific vaccination strategies against cancer
35. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine
36. Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal
37. Glioma immunology and immunotherapy
38. Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis
39. Immunohistological study of mononuclear cell infiltrate in malignant gliomas
40. Primary tumours of neuro-ectodermal origin
41. Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines
42. Inflammatory infiltrates and natural killer cell presence in human brain tumors
43. Cell-based vaccination against melanoma - Background, preliminary results, and perspective
44. Brain tumor survival: Results from the National Cancer Data Base
45. Progress in active-specific immunotherapy of brain malignancies
46. In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats
47. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain
48. Signaling defects in T lymphocytes of patients with malignancy
49. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells
50. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration